157 related articles for article (PubMed ID: 27934506)
1. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
[TBL] [Abstract][Full Text] [Related]
2. A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).
Thaisrivongs DA; Morris WJ; Tan L; Song ZJ; Lyons TW; Waldman JH; Naber JR; Chen W; Chen L; Zhang B; Yang J
Org Lett; 2018 Mar; 20(6):1568-1571. PubMed ID: 29481097
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
4. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
[TBL] [Abstract][Full Text] [Related]
5. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
[TBL] [Abstract][Full Text] [Related]
8. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
[TBL] [Abstract][Full Text] [Related]
9. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
[TBL] [Abstract][Full Text] [Related]
11. Quantification and pharmacokinetic property of verubecestat an BACE1 inhibitor in rat plasma.
Wang Q; Wang H; Zhong Y; Mei Y
Biomed Chromatogr; 2020 Feb; 34(2):e4715. PubMed ID: 31633829
[TBL] [Abstract][Full Text] [Related]
12. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
Doggrell SA
Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
[No Abstract] [Full Text] [Related]
13. BACE inhibitor bust in Alzheimer trial.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
[No Abstract] [Full Text] [Related]
14. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
Dotsenko VV; Chigorina EA; Krivokolysko SG
Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Qu L; Ji L; Wang C; Luo H; Li S; Peng W; Yin F; Lu D; Liu X; Kong L; Wang X
Eur J Med Chem; 2021 Jul; 219():113441. PubMed ID: 33862517
[TBL] [Abstract][Full Text] [Related]
16. Macrocyclic glycopeptide chiral selectors bonded to core-shell particles enables enantiopurity analysis of the entire verubecestat synthetic route.
Barhate CL; Lopez DA; Makarov AA; Bu X; Morris WJ; Lekhal A; Hartman R; Armstrong DW; Regalado EL
J Chromatogr A; 2018 Mar; 1539():87-92. PubMed ID: 29397980
[TBL] [Abstract][Full Text] [Related]
17. Bad news and good news in AD, and how to reconcile them.
Knopman DS
Nat Rev Neurol; 2019 Feb; 15(2):61-62. PubMed ID: 30622292
[No Abstract] [Full Text] [Related]
18. β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
Selkoe D
Lancet Neurol; 2019 Jul; 18(7):624-626. PubMed ID: 31202466
[No Abstract] [Full Text] [Related]
19. Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.
Crunkhorn S
Nat Rev Drug Discov; 2016 Dec; 16(1):18. PubMed ID: 28031572
[No Abstract] [Full Text] [Related]
20. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
